Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Apr 1, 2010 in Foundation NewsLine, Type C |

Health Canada Approves Zavesca for Use in Niemann-Pick Type C; First Authorized Treatment in Canada

Health Canada recently announced its approval of the drug Zavesca (miglustat) as the first authorized treatment for neurological symptoms of Niemann-Pick Disease Type C (NPC). Zavesca is not a cure for NPC, but it has shown promise in treating symptoms related to NPC and in slowing the progression of the disease for some patients.

For more details, click here.